Valsartan is commonly used across therapeutic domains where additional symptomatic support is needed for managing certain cardiovascular conditions. Main indications include: high blood pressure (hypertension), symptomatic heart failure (NYHA class II–IV), and managing individuals with left ventricular failure or dysfunction following a myocardial infarction (heart attack).

For patients dealing with these conditions, the therapy may assist with easing the overall symptom burden. It is applied across domains where additional symptomatic support is needed, particularly when symptoms related to systemic imbalance or heightened physiological activity are present. This supportive assistance is relevant in contexts involving heightened systemic burden and assists with maintaining functional stability.

The goal is to support the patient during episodes of heightened discomfort by easing distress. As one patient benefit suggests: “The medication contributes to easing the overall symptom load during symptomatic periods.” The therapy is applied when appropriate as part of a comprehensive management plan.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

The eligibility for using Valsartan DENK is strictly defined by regulatory documentation concerning age, physiological status, and coexisting medical conditions.

Populations for Whom Use is Established

Valsartan is approved for use in adults across its primary labeled indications. It is also approved for treating hypertension in children and adolescents aged 6 to less than 18 years.

Absolute Contraindications (Must Not Use)

Use is formally contraindicated in the following populations:

• Pregnancy: All trimesters, with mandatory discontinuation upon detection of pregnancy due to the risk of fetal injury and death.
• Hypersensitivity: Patients with an allergy to valsartan or any of the inactive ingredients.
• Severe Hepatic Impairment: Including patients diagnosed with biliary cirrhosis or cholestasis.
• Dual RAS Blockade: Patients with diabetes mellitus or moderate-to-severe renal impairment (GFR <60 mL/min/1.73m²) who are concomitantly receiving aliskiren.

Restricted or Not Recommended Use

• Age-Related: Use is not recommended in children under 6 years of age. It is also not recommended for heart failure or post-myocardial infarction in pediatric patients under 18 years old.
• Organ Function: Caution and close monitoring are necessary in patients with mild to moderate hepatic impairment. Use is not recommended for patients with severe renal impairment (Creatinine Clearance <10 mL/min) or pediatric patients with creatinine clearance <30 mL/min.
• Lactation: Breastfeeding mothers are generally not recommended to use valsartan.

The official interaction profile for Valsartan identifies specific constraints on co-administration with other medicines and products.

Interaction-Related Restrictions

The combination of Valsartan with Aliskiren is strictly contraindicated in patients with diabetes mellitus or those with renal impairment (Glomerular Filtration Rate GFR < 60 mL/min/1.73 m^2) due to the associated risks of dual Renin-Angiotensin System blockade. Concomitant use with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium is not recommended due to the officially documented risk of an additive effect leading to hyperkalemia (increased serum potassium).

Exposure-Modifying Agents

Valsartan is a substrate for the drug transporters OATP1B1 and MRP2. Inhibitors of these transporters, such as Rifampin, may formally increase the systemic exposure to Valsartan. Co-administration with Lithium is documented to result in increases in serum lithium concentrations and risk of lithium toxicity. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a loss of antihypertensive effect and an increased risk of renal impairment, particularly in the elderly or volume-depleted populations.

Food and Metabolism

Regulatory documents indicate that Valsartan may be taken with or without food, as no clinically significant interaction with food has been documented. Furthermore, CYP 450-mediated drug interactions are officially considered unlikely.

Valsartan DENK is pharmacologically classified as a selective and competitive Angiotensin II type 1 receptor antagonist (AT1 receptor blocker). The AT1 receptor is the key biological target, primarily expressed on the surfaces of vascular smooth muscle cells, as well as in the adrenal glands, heart, and kidneys. Valsartan's mechanism of action involves binding to the AT1 receptor site with selective affinity, thereby preventing the endogenous ligand, Angiotensin II, from initiating its signaling effects. This binding is purely inhibitory and does not activate the receptor itself.

Valsartan interrupts the Renin-Angiotensin-Aldosterone System (RAAS) pathway downstream of Angiotensin-Converting Enzyme (ACE). By blocking the AT1 receptor, Valsartan prevents Angiotensin II from mediating its typical effects, which include vasoconstriction and the stimulation of aldosterone release. The consequence of this blockade is the inhibition of intracellular signaling cascades that lead to the contraction of arterial smooth muscle. This interruption results in the direct system-level physiological modulation of arterial smooth muscle relaxation and, subsequently, reduced peripheral vascular resistance.

Official Administration Guidelines

Valsartan DENK is administered through the oral route as a film-coated tablet for long-term management of approved conditions. The tablets may be taken with or without food and are typically swallowed whole. The total daily dosage and frequency are determined by the specific condition being addressed.

---

Feature	Guideline Statement
Route	Oral administration.
Dosing Schedule	Indication-specific. Hypertension: 80 mg or 160 mg once daily, ranging up to 320 mg daily. Heart Failure: Starting dose of 40 mg twice daily.
Frequency	Once daily for hypertension; Twice daily for heart failure and post-myocardial infarction.
Titration Rule	Doses for heart failure are increased in steps (titration) at intervals of at least two weeks to reach the highest tolerated dose.
Special Populations	No initial adjustment is required for older adults or in mild to moderate renal impairment. Pediatric dosing is weight-based for hypertension.
Missed Dose	If a dose is missed, it should be skipped if the next scheduled dose is near; the patient should resume the regular dosing time.

---

Procedural Structure

The instructions for use describe that the medicine must be taken by mouth, either once or twice a day, independent of meals. Therapy begins at a specific low starting dose for the given indication, such as 40 mg twice daily for heart failure. This initial dose is then systematically titrated upward over a period of weeks to reach a target maintenance dose, not exceeding the maximum daily dose of 320 mg.

Evidence for Use in High Blood Pressure (Hypertension)

Research exploring the use of Valsartan in patients with high blood pressure has involved large-scale, long-term Randomized Controlled Trials (RCTs). These studies included adults and pediatric patients, and aimed to provide balanced tracking of outcomes over time. Researchers monitored changes in blood pressure (BP) and the incidence of major cardiovascular events. Findings reported both short-term and later changes in BP levels, and described observed differences when compared to active control medicines. The extent of long-term data for children and adolescents across various pre-existing conditions is not fully established, and comparative evidence is sometimes lacking.

---

Evidence for Use in Symptomatic Heart Failure

The clinical evaluation for symptomatic heart failure includes large-scale, double-blind, placebo-controlled RCTs applied to adults with a reduced ejection fraction. Researchers monitored composite endpoints, such as the study-defined composite of clinical outcomes (including hospitalization), and tracked clinical markers of heart function. Trials reported on the observed rates for the composite endpoint compared to placebo. Evidence remains limited when Valsartan is used as a single agent, and findings for its simultaneous use with certain other heart medications described adverse event rates that were not offset by improved outcomes.

---

Evidence for Use Following a Heart Attack (Post-Myocardial Infarction)

This research involved large, multinational, active-controlled RCTs in adults stable after an acute heart attack complicated by heart failure or left ventricular systolic dysfunction. Outcomes monitored included the study-defined endpoint of all-cause death and composite endpoints tracking events like stroke. Trials reported on the observed rates of all-cause death compared to an established active control medicine. A key limitation is that follow-up durations were limited, as the key trials did not provide data beyond approximately three years.

---

Research Gaps and Uncertainty

Research provides information on short-term changes and specific group patterns, but long-term effects are not fully established across all indications. Evidence quality varies across studies, and data for certain high-risk groups or complex co-existing conditions remains insufficient. Results reflect patterns derived only from the specific populations studied.

Common questions about Valsartan DENK (FAQ)

---

Q: Can Valsartan DENK cause a dry, irritating cough, similar to some other blood pressure medicines?

The official product information lists cough as an uncommon side effect reported during clinical trials. Unlike some other classes of blood pressure medicine, regulatory documents for Valsartan do not specifically describe the cough as being dry or irritating. However, the occurrence of cough has been noted in the product summary.

---

Q: Is it possible for Valsartan DENK to cause back pain or joint stiffness?

Back pain is described as a common adverse reaction in some patient groups, particularly those studied for heart failure. Joint pain, referred to as arthralgia, has also been reported in the post-marketing setting. However, the official documentation does not specifically mention joint stiffness as a reported side effect.

---

Q: Does Valsartan DENK have any reported effect on body weight?

The regulatory adverse reaction lists for the single-ingredient product, Valsartan, do not list weight gain or weight loss as a common or uncommon side effect.

---

Q: Are there any specific blood tests required while taking Valsartan DENK?

Regulatory documents note the importance of periodic monitoring of specific lab values. These specific values include renal function (how well the kidneys are working) and serum potassium levels. Monitoring is described as necessary for patients who have pre-existing kidney issues or heart failure.

---

Q: What kind of foods or drinks, if any, should be limited while taking Valsartan DENK?

The official documents state that Valsartan DENK can be taken with or without food, as no clinically significant interaction has been documented. However, regulatory information notes that co-administration with salt substitutes that contain potassium is not recommended due to the potential risk of hyperkalemia (high potassium levels).

---

Q: What happens if a person taking Valsartan DENK experiences severe vomiting or diarrhea?

Conditions that cause substantial loss of body fluid, such as severe vomiting or diarrhea, can lead to a drop in blood pressure. The drug's effects, combined with fluid loss, may increase the risk of low blood pressure. Official patient information describes this as a situation where consultation with a healthcare provider is noted.

---

Q: Can taking Valsartan DENK make a person more sensitive to hot weather or dehydration?

Official patient information indicates that this medicine can make a person more susceptible to dehydration through excessive sweating. Patient guidance suggests maintaining adequate hydration, especially during exercise or prolonged exposure to hot weather.

---

Q: Is it possible to use Valsartan DENK for non-approved conditions like migraine prevention?

The medicine is not indicated or approved by regulatory bodies for the prevention of migraines. Valsartan’s officially approved uses include the treatment of high blood pressure (hypertension), symptomatic heart failure, and after a heart attack (post-myocardial infarction).

---

Q: Does the generic version of Valsartan DENK work the same way as the brand-name version?

Regulatory agencies, such as the FDA, require generic versions to be bioequivalent to the brand-name product. This means that generic drugs are required to have the same active ingredient and demonstrate bioequivalence, meaning they are expected to work similarly and provide the same clinical benefit.

---

Q: What are the symptoms of severely low blood pressure from Valsartan DENK?

Low blood pressure, or hypotension, is a known risk. Symptoms of severe hypotension may include feelings of dizziness or lightheadedness, and in some cases, fainting. These symptoms can be particularly noticeable when changing position rapidly, such as standing up from a sitting or lying position.

---

Q: Is there any information on how Valsartan DENK affects different patient populations, such as Black patients?

The regulatory label notes that some blood pressure-lowering drugs, when used alone (as monotherapy), may have a smaller effect on blood pressure in Black patients compared to other populations. This consideration is noted in official guidance used for making treatment decisions.

---

Q: Can Valsartan DENK cause problems with sleep, such as insomnia?

Insomnia, which is difficulty sleeping, has been reported in post-marketing surveillance for Valsartan. This indicates that while it may not be a common event, it has been noted in patients after the medicine was approved and released.

---

Q: Does Valsartan DENK have any reported effects on vision or the eyes?

The reported side effects list for Valsartan includes vertigo, which is a specific type of dizziness or a sensation of spinning, though general vision effects are not commonly listed. Other ocular effects may be noted in official post-marketing reports or summaries.

---

Q: Is it safe to drink alcohol while taking Valsartan DENK?

Official drug interaction guidance indicates that alcohol may have an additive effect in lowering blood pressure. This combination can increase the risk of low blood pressure, which may lead to symptoms like dizziness, lightheadedness, or fainting.

---

Q: Are there any reported instances of skin changes or rashes while taking Valsartan DENK?

Rash has been listed as a reported side effect of Valsartan. Additionally, more serious hypersensitivity reactions, including angioedema (swelling of the face, lips, or throat) and bullous dermatitis (a severe skin condition), have been reported in post-marketing surveillance.

---

Q: What should a patient know about taking this medicine if they are already on a diuretic (water pill)?

Taking Valsartan with a diuretic (water pill) can increase the risk of low blood pressure (hypotension). Regulatory guidance highlights the importance of close monitoring, especially if a high dose of the diuretic has recently been initiated, or if the patient is otherwise at risk of low blood pressure.

---

Q: Can Valsartan DENK affect cholesterol or triglyceride levels?

Changes in cholesterol or triglyceride levels are not listed as common or uncommon adverse reactions in the official monotherapy label for Valsartan.

---

Q: Does the official information mention any effect of Valsartan DENK on erectile function?

Impotence, or erectile dysfunction, has been reported in post-marketing surveillance as a very rare side effect. This is noted in official summaries as a potential, though infrequent, adverse reaction.

How to Store and Dispose of Valsartan DENK

All storage and disposal requirements for Valsartan DENK are strictly defined by official regulatory documentation to ensure product integrity and public safety.

Storage Requirements

Valsartan tablets must be stored at room temperature, typically below 30C (86F), and maintained in their original container to provide protection from moisture and light.

It is a mandatory regulatory requirement that the medicine be stored out of the sight and reach of children to prevent accidental ingestion. For non-tablet formulations, stability limits apply; for example, prepared oral suspension must be discarded after 30 days if stored at room temperature.

Disposal Instructions

Unused or expired Valsartan DENK must not be disposed of in household waste or via wastewater (flushing down the toilet or sink).

Patients should return the unused or expired medication to a pharmacy or official medicine collection program that follows local regulatory guidelines for pharmaceutical waste.